Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
Status:
Unknown status
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if VT-122 provides a clinical benefit when added to
Sorafenib in patients with advanced hepatocellular carcinoma (HCC).